Looks like you’re on the UK site. Choose another location to see content specific to your location
Merck to expand manufacturing capabilities of Italian site
Merck has announced plans to add an extra production line at its manufacturing site of Bari, Italy.
The company will spend 35 million euros (31.21 million pounds) to create a new production line for the aseptic filling of biotech medicines under isolator, which will be fully operational by 2022.
It will be equipped with an isolator designed with the latest technologies, offering a high level of automation and conforming to best practice standards in aseptic filling, a prerequisite to ensure the safety of injectable medicines.
This new production line will support the creation of new biotech medicines in the areas of multiple sclerosis, fertility and endocrinology, with a capacity of 14 million units per year.
Stefan Oschmann, chairman of the executive board and chief executive officer of Merck, said: "This investment underpins the importance of the Modugno-Bari production site for our growing healthcare business."
Merck's biotech manufacturing site in Bari was first established in 1992 and has grown over time, currently employing 225 people and producing medicines supplied to more than 150 countries.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard